What does Immunovant do?
Immunovant, Inc. trades on Nasdaq under ticker IMVT and is a clinical-stage immunology company developing antibody medicines for autoimmune diseases. Its central asset is IMVT-1402, or imeroprubart, a fully human monoclonal antibody that inhibits FcRn. The FY2026 Form 10-K reports no approved products or product revenue.
What is FcRn, and why is it the center of the strategy?
FcRn protects immunoglobulin G antibodies from degradation. In several autoimmune diseases, pathogenic IgG drives tissue damage or abnormal signaling. Blocking FcRn accelerates IgG removal. Immunovant tests this mechanism across endocrinology, rheumatology, neurology and dermatology; its official pipeline lists six indications.
Why does Immunovant matter despite having no sales?
Immunovant matters as a focused test of whether deeper IgG reduction, weekly subcutaneous dosing and a potentially favorable safety profile can improve on a validated drug class. Its analytical unit is not revenue by segment, but the probability-adjusted value of each indication and the shared cash required to reach decisive data. The same molecule may create operating leverage across diseases, but clinical setbacks are also correlated across the portfolio.
How does Immunovant expect to make money?
Immunovant finances research with equity rather than customer receipts. If IMVT-1402 is approved, the model would shift to selling a specialty biologic through focused commercial teams. Revenue would depend on treated patients, net price, payer access and treatment persistence. Before approval, clinical evidence creates or destroys value.
Where would the economics come from?
The upside is a shared platform: one manufacturing process, safety database and overlapping commercial infrastructure supporting several indications. Graves’ disease could anchor endocrinology; MG and CIDP are established FcRn markets; RA, Sjögren’s disease and CLE offer expansion. This leverage exists only after approval.
How does the HanAll license change the economics?
| Economic term | Official disclosure | Analytical implication |
|---|---|---|
| Territory | Exclusive rights in major Western markets under the December 2017 agreement. | Controls major markets, but not worldwide rights. |
| Upfront assignment | $37.8M assignment price in December 2018. | The core asset was licensed. |
| Future milestones | Up to $420.0M remained at March 31, 2026, after $32.5M paid. | Success creates additional cash obligations. |
| Royalties | Mid-single-digit to mid-teens royalties on net sales. | Sales exceed the economics retained by Immunovant. |
| Development burden | Immunovant funds development and commercialization in its territory. | The company bears most pre-launch capital risk. |
The license is both asset and dependency. Loss of rights could stop development, while success activates milestones and royalties that reduce retained economics.
Which IMVT-1402 programs matter most?
How large are the company-defined unmet-need populations?
What are the most important trial milestones?
| Program | Design or scale | Expected milestone | Why it matters |
|---|---|---|---|
| D2T RA | 170 participants in Period 1; 600 mg weekly subcutaneous dosing. | Further update in second-half calendar 2026. | Tests blinded durability after the open-label response. |
| CLE | Fully enrolled randomized Phase 2b proof-of-concept study. | Top-line results in second-half calendar 2026. | Tests early case evidence in a controlled study. |
| Graves’ disease | Two potentially registrational studies. | Top-line results in calendar 2027. | Central to the first-launch thesis. |
| Myasthenia gravis | Potentially registrational study. | Top-line results in calendar 2027. | Directly faces approved FcRn medicines. |
| Sjögren’s disease | Approximately 180 planned participants; 600 mg, 300 mg or placebo. | Top-line results in calendar 2028. | Could broaden the rheumatology franchise. |
| CIDP | Approximately 162 planned participants; 24-week controlled period. | Top-line results in calendar 2028. | Must differentiate in an established market. |
What do Immunovant’s latest results show?
The freshest package is the May 20, 2026 update. With no revenue, spending, liquidity and clinical evidence are the key results.
What changed in the fiscal fourth quarter?
| Latest-period item | Q4 FY2026 | Q4 FY2025 | Interpretation |
|---|---|---|---|
| R&D expense | $142.3M | $93.7M | IMVT-1402 activity and the $39.0M discontinuation charge raised spending. |
| Non-GAAP R&D | $136.0M | $87.2M | Underlying development spending also increased. |
| G&A expense | $17.3M | $20.2M | Corporate overhead declined. |
| Net loss | $147.9M | $106.4M | Clinical spending widened the loss. |
| Stock-based compensation | $11.1M | $11.7M | Non-cash pay was not the main driver. |
| Common shares outstanding | 203.9M at March 31, 2026 | Not used as a period comparison | Repeated equity financing matters for per-share value. |
What did the clinical update add?
The D2T RA result is encouraging, not registrational proof. Period 1 was open label, although independent assessors were blinded to treatment status. The cohort was heavily pretreated: 86.7% had failed two advanced-therapy mechanisms, with 12.8 years of mean disease duration. Blinded durability is the next test.
How financially strong is Immunovant?
Immunovant has a strong clinical-stage balance sheet, but it is not self-funding. Cash increased because financing exceeded burn. The December 2025 offering produced $543.7M of net proceeds, and FY2026 option exercises added $52.1M.
| Financial measure | FY2026 or March 31, 2026 | FY2025 or March 31, 2025 | Research implication |
|---|---|---|---|
| Cash and cash equivalents | $902.1M | $714.0M | Liquidity is high, but equity-funded. |
| Total assets | $957.0M at March 31, 2026 | $776.2M at March 31, 2025 | Assets are mainly liquid. |
| Total liabilities | $104.4M at March 31, 2026 | $68.8M at March 31, 2025 | Accrued costs matter more than debt. |
| R&D expense | $456.7M in FY2026 | $360.9M in FY2025 | R&D rose 26.5%. |
| G&A expense | $76.2M in FY2026 | $77.2M in FY2025 | Overhead was stable. |
| Net loss | $505.6M in FY2026 | $413.8M in FY2025 | The loss represents financing need. |
| Net cash used in operations | $407.3M in FY2026 | $375.9M in FY2025 | Operating burn is the key cash KPI. |
How long can the cash support the plan?
Management says March 31, 2026 cash can fund announced indications through a potential Graves’ disease launch. As a sensitivity check, $902.1M divided by FY2026 operating cash use of $407.3M equals about 2.2 years of historical burn, not guidance.
Where is R&D capital being deployed?
Unallocated FY2026 R&D included $128.5M of personnel expense, $39.0M of batoclimab discontinuation cost and $43.9M of other costs. A $22.8M manufacturing commitment at May 20, 2026 was split between FY2027 and FY2028.
What strategic turning points shaped Immunovant?
-
2017Roivant signed the HanAll license that underpins the anti-FcRn strategy.
-
2018Immunovant assumed the rights and obligations for $37.8M.
-
2019The public-company combination closed and the Immunovant name was adopted.
-
2022IMVT-1402 was introduced as a next-generation anti-FcRn candidate.
-
2023Initial Phase 1 data supported deep IgG reduction and broad development.
-
2024A U.S. patent extended to June 23, 2043 before potential extension.
-
2025Eric Venker became CEO and the pipeline expanded into Sjögren’s disease and CLE.
-
2026Two batoclimab TED trials failed; resources shifted fully to IMVT-1402.
What did the shift away from batoclimab change?
The April 2026 pivot simplified the thesis and focused capital on the preferred molecule. It also created $42.5M of accumulated non-cancelable costs at March 31, 2026, including $39.0M recognized in FY2026 R&D, and triggered discussions over batoclimab rights. The strategic benefit is clearer resource allocation; the cost is the loss of a backup commercial asset.
Immunovant’s current story is no longer “two FcRn assets create optionality.” It is “one next-generation asset must justify a broad, expensive portfolio.”
Batoclimab still contributed trial knowledge, investigator relationships and disease data. Whether those advantages offset lost time and capital is now testable. The patent announcement and 2022 asset launch show that the successor plan predated the pivot.
What gives Immunovant a competitive advantage?
Immunovant has no commercial moat yet. Its potential advantage combines deep IgG reduction, weekly subcutaneous dosing, possible self-administration, broad indication coverage and patent protection. It also has accumulated FcRn trial experience and an R&D-heavy workforce.
Where is the differentiation strongest?
The matrix interprets official disclosures, not market share. Immunovant must gain approval and reimbursement without losing its proposed clinical differentiation.
Who are the main competitors?
| Competitor or class | Relevant position cited in Immunovant’s FY2026 filing | Pressure on Immunovant |
|---|---|---|
| Argenx / efgartigimod | Approved in generalized MG and CIDP; additional Graves’ disease development announced. | Sets FcRn benchmarks for efficacy, convenience and access. |
| Johnson & Johnson / nipocalimab | Approved for MG in adult and pediatric patients aged 12 and older with specified antibodies. | Large-company resources intensify rivalry. |
| UCB / rozanolixizumab | Approved for generalized MG in specified antibody-positive adults. | Raises the evidence standard in neurology. |
| Complement and B-cell therapies | Approved or developing alternatives in MG and other autoimmune diseases. | Competition extends beyond the FcRn class. |
| Disease-specific emerging agents | Multiple Graves’ disease and CIDP candidates were in early- or late-stage development at March 31, 2026. | First-in-indication windows can narrow. |
A moat would come from outcomes plus execution. Patents protect the molecule, but physicians and payers compare efficacy, safety, dosing and cost. The September 2023 Phase 1 results established the pharmacodynamic premise; late-stage trials must establish the commercial one.
Who owns Immunovant stock, and why does control matter?
The 2026 proxy identifies Roivant Sciences as Immunovant’s controlling stockholder. Its ownership, preferred rights and board ties shape financing and governance.
How concentrated is ownership?
| Holder or group | Shares | Economic stake | Governance implication |
|---|---|---|---|
| Roivant Sciences Ltd. | 113,327,007 at June 30, 2026 | 54.9% | Majority holder and owner of all 10,000 Series A preferred shares. |
| FMR LLC | 14,729,555 at June 30, 2026 | 7.1% | Significant outside institution, but not a controller. |
| Current directors and executive officers | 3,972,516 for 11 individuals at June 30, 2026 | 1.9% | Equity incentives align management; direct ownership is modest. |
| Public common shares | 206,264,878 denominator at June 30, 2026 | One vote per common share | Minority influence comes mainly through market discipline. |
What does controlled-company status change?
Nasdaq controlled-company exemptions apply while Roivant holds majority voting power or its preferred directors control board votes. Four directors were independent in the 2026 proxy; CEO Eric Venker and two Roivant-affiliated directors were not. The structure supports coordination but gives minority holders fewer governance protections.
Venker became CEO in April 2025 while retaining a Roivant role. The leadership update framed this as a growth transition. Related-party services and future financings belong in the core analysis.
What opportunities could expand Immunovant’s value?
The opportunity is to turn one molecule into several franchises. Established FcRn indications reduce mechanism risk but intensify competition; new indications offer more whitespace but greater clinical uncertainty. Portfolio sequencing therefore matters.
Which catalysts matter most?
Graves’ disease is the central differentiation case. Current care uses antithyroid drugs, radioactive iodine or surgery. Batoclimab data suggested responses could persist after treatment, but IMVT-1402 must prove this in randomized registrational trials.
Shared manufacturing, clinical operations and commercial infrastructure could lower incremental costs after launch. Before approval, breadth can instead slow enrollment and raise cash needs. New indications add value only when expected returns exceed their execution burden. Commercial preparation is another option: early payer research, medical-affairs education and supply planning can shorten launch execution, but spending too early would reduce runway if pivotal data disappoint.
What risks could weaken Immunovant’s outlook?
Risk is concentrated: one molecule drives prospective value, trials drive spending, equity funds operations and Roivant controls governance. The FY2026 filing also highlights regulatory, manufacturing, clinical-site, privacy and intellectual-property risks.
Which risks have the clearest financial impact?
| Risk | Company-specific evidence | Financial line affected | What to monitor |
|---|---|---|---|
| Clinical failure | Two batoclimab TED trials missed endpoints in April 2026. | Pipeline value and R&D cost. | Randomized efficacy, safety and discontinuations. |
| Single-asset concentration | Resources are now focused on IMVT-1402. | Enterprise value and revenue assumptions. | Cross-indication consistency. |
| Financing and dilution | FY2026 financing inflow was $595.8M; operations used $407.3M. | Share count and cost of capital. | Runway, expansion and ATM use. |
| License dependency | Core rights depend on HanAll; up to $420.0M remained. | Milestones, royalties and legal rights. | Rights discussions and compliance. |
| Manufacturing | CMO reliance and a $22.8M commitment were disclosed. | R&D cost, launch timing and margins. | Validation, supply and unit cost. |
| Competition | Approved FcRn drugs serve MG and CIDP. | Penetration, price and selling expense. | Labels, dosing and reimbursement. |
| Controlled governance | Roivant owned 54.9% at June 30, 2026. | Transactions and minority influence. | Board independence and ownership changes. |
The scorecard is a qualitative synthesis, not a rating. The largest risk is correlated failure: a molecule-wide safety, efficacy or manufacturing issue could impair every indication at once.
What is the key takeaway for valuation and research?
A current-revenue DCF is not useful because Immunovant had no FY2026 product sales. Use risk-adjusted net present value by indication, modeling eligible patients, penetration, net price, duration, launch timing, approval probability, margins, royalties, milestones, taxes and shared expense. Add cash and model dilution explicitly.
Which variables belong in a serious model?
Supports include a validated mechanism, a potentially differentiated molecule, multiple late-stage programs, substantial March 2026 cash and long-dated patents. Offsetting factors are no revenue, one-asset concentration, rising burn, licensed economics, competition and controlled governance.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.